title: Comparison of self-administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design.
abstract: OBJECTIVE
  To compare the impact of 1000-microgram self-administered vaginal misoprostol versus self-administered vaginal placebo at home on preoperative cervical ripening in both premenopausal and postmenopausal women prior to outpatient resectoscopy.
  
  
  METHODS
  Randomised, double-blind, placebo-controlled sequential trial.
  
  
  METHODS
  Norwegian university teaching hospital.
  
  
  METHODS
  Premenopausal and postmenopausal women referred to outpatient resectoscopy.
  
  
  METHODS
  The women were randomised to either 1000 micrograms of self-administered vaginal misoprostol or self-administered vaginal placebo the evening before outpatient resectoscopy.
  
  
  METHODS
  Preoperative cervical dilatation, acceptability and complications.
  
  
  RESULTS
  (a) Intraoperative findings and distribution of cervical dilatation in the two treatment groups. Values are given as median (range) or n (%). (b) Acceptability in the two treatment groups. Values are given as completely acceptable, n (%); fairly acceptable, n (%); fairly unacceptable, n (%) and completely unacceptable, n (%). (c) Pain in the two treatment groups. Pain was measured with a visual analogue scale score, scale ranges from 0 (no pain) to 10 (unbearable pain). Values are given as median (range). (d) Occurrence of adverse effects in the two treatment groups. Values are given as n (%). (e) Complications, given as n (%).
authors.affiliation: Department of Gynaecology, Helse Finnmark, Klinikk Hammerfest, Hammerfest, Norway. kevin.s.oppegaard@helse-finnmark.no
authors.forename: K S
authors.initials: KS
authors.lastname: Oppegaard
authors.forename: B-I
authors.initials: BI
authors.lastname: Nesheim
authors.forename: O
authors.initials: O
authors.lastname: Istre
authors.forename: E
authors.initials: E
authors.lastname: Qvigstad
mesh_terms: D000282:Administration, Intravaginal; D000284:Administration, Oral; D000328:Adult; D000553:Ambulatory Care; D020070:Cervical Ripening / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015907:Hysteroscopy / Q000379:methods*; D016595:Misoprostol / Q000008:administration & dosage*; D010120:Oxytocics / Q000008:administration & dosage*; D017060:Patient Satisfaction; D017698:Postmenopause; D011183:Postoperative Complications / Q000517:prevention & control*; D011247:Pregnancy; D017697:Premenopause; D011300:Preoperative Care / Q000379:methods; D012646:Self Administration; D016896:Treatment Outcome; D014591:Uterine Diseases / Q000601:surgery*
chemical_list: D010120:Oxytocics; D016595:Misoprostol